OncoMatch/Clinical Trials/NCT06852222
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Is NCT06852222 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Bleximenib and Venetoclax (VEN) for leukemia, myeloid, acute.
Treatment: Bleximenib · Venetoclax (VEN) · Azacitidine (AZA) — The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: KMT2A (MLL) rearrangement
Required: NPM1 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Kidney function
adequate renal function required
Liver function
adequate hepatic function required
Participants must have adequate hepatic and renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cancer Treatment Center of America Phoenix · Goodyear, Arizona
- University of Arkansas at Little Rock · Little Rock, Arkansas
- City of Hope · Duarte, California
- Memorial Regional Hospital · Hollywood, Florida
- Jupiter Research · Jupiter, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify